Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
There are MDR pathogens, and there is carbapenem-resistant A. baumannii, aka CRAB. This surely must be one of the most formidable bacterial organisms. It has resistance mechanisms second to none. When found in patients, it is very difficult to eradicate and extremely difficult to get rid off, once established in Continue reading Treating Serious CRAB Infections
WHO compiles a list of antibacterials in clinical development on a regular basis, the last in mid-2024 [1]. The information is up-to-date and detailed: it provides MoA and antibacterial spectrum, coverage of problem pathogens, the development phase, and whether it can be considered an ‘innovative’ drug (based on a set Continue reading A Critical Review of WHO’s List of Antibacterials in Clinical Development
Besides ceftriaxone (CTRIAX), cefixime and spectinomycin we have no other highly effective single-dose treatment regimens for urogenital GC. Failures of all 3 drugs have been described but remain rare, can be overcome with higher doses of CTRIAX (1 g instead of 250 mg IM) or with azithromycin combination therapy. Worse Continue reading GC Therapy – Shooting for the Stars